Arsanis is a clinical-stage biopharmaceutical company developing targeted monoclonal antibodies for pre-emptive and post-infection treatment of serious bacterial and viral diseases. Its lead program, ASN100—a combination of two human mAbs, ASN-1 and ASN-2—broadly neutralizes six Staphylococcus aureus cytotoxins and has received FDA Fast Track designation. A global Phase 2 study of a single dose of ASN100 versus placebo for prevention of S. aureus pneumonia in high-risk mechanically ventilated patients is underway, with data anticipated in 2018. The company plans to complete the ASN100 Phase 2 study and to advance preclinical gram-negative programs and its respiratory syncytial virus (RSV) program toward the clinic. Arsanis is also conducting discovery research in neonatal S. aureus sepsis with the potential for future funding to advance a neonatal sepsis candidate. The company is headquartered in Waltham, Massachusetts, with European research and preclinical development operations in Vienna, Austria. Arsanis is developing human monoclonal antibodies targeting severe infectious diseases, with a lead program ASN-100 — a monoclonal antibody cocktail for hospital-associated Staphylococcus aureus infections — currently in manufacture for clinical trials. The company’s pipeline includes preclinical programs against multi-drug resistant gram-negative pathogens Escherichia coli and Klebsiella pneumoniae, plus a program targeting Streptococcus pneumoniae. Arsanis combines in-house infectious disease expertise with antibody discovery and optimization through a partnership with Adimab LLC. Founded in 2010, the company plans to use recent funding to advance ASN-100 into clinical development while maturing its broader anti-infective antibody portfolio. Financially, Arsanis closed a $20 million Series B and has secured over $7 million in non-dilutive grant funding, with potential for an additional $20 million of grant support over the next three years. Leadership includes co-founder and Chief Scientific Officer Eszter Nagy and co-founder/chair Tillman Gerngross; Dr. Claudio Nessi of NeoMed will join the board as part of the recent financing. Arsanis focuses on development of monoclonal antibody therapeutics targeting severe infectious diseases, including antibiotic-resistant pathogens and infections in immune-compromised patients. The company uses first-in-class monoclonal antibody discovery technologies to select highly potent antibodies with unique qualities. Its pipeline is at pre-clinical stage, with plans to advance the most successful programs into clinical proof-of-relevance studies. Proceeds from its recent financing will support several pre-clinical proof-of-concept programs across anti-microbial infectious disease targets. The company was founded in fall 2010 by Dr. Eszter Nagy, Dr. Tillman Gerngross and Errik Anderson, and will initiate operations in Vienna, Austria. Management emphasizes building a broad portfolio of infectious disease targets and advancing programs based on pre-clinical success.

Total raised

$76M

Funding rounds

3

Latest round

Series D

Latest activity

Apr 2017